Context Therapeutics' $100M placement; Blueprint raises guidance for rare disease drug
Plus, news about Novocure and Corvus:
Context Therapeutics’ $100M PIPE: Nextech led the private placement, and other investors like Ally Bridge Group took part. The solid tumor biotech also said the FDA cleared human testing of the company’s bispecific antibody CTIM-76. — Kyle LaHucik
Blueprint Medicines raises sales guidance, stock jumps 15%: The company’s rare disease drug Ayvakit generated $92.5 million in revenue in the first quarter of 2024, and Blueprint is now raising its guidance on annual sales of the drug by $20 million to $410 million. The treatment’s label was expanded last year to a broader patient population that includes those with indolent systemic mastocytosis, a rare disease in which too many of a kind of white blood cell build up in the body. — Lei Lei Wu
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
